重复经颅磁刺激联合普拉克索治疗中晚期帕金森病合并抑郁的疗效观察

Clinical efficacy of repetitive transcranial magnetic stimulation and pramipexole in mid and late Parkinson’s disease with depression

关键词:  经颅磁刺激  普拉克索  帕金森病  抑郁

Key words:  transcranial magnetic stimulation  pramipexole  Parkinson’s disease  depression

摘要:

摘　要：目的　观察重复经颅磁刺激（rTMS）联合普拉克索治疗中晚期帕金森病（PD）合并抑郁患者的疗效。方法 92 例中晚期PD合并抑郁患者随机采用普拉克索（对照组）或rTMS联合普拉克索治疗（观察组）12 周。采用汉密尔顿抑 郁量表（HAMD）、帕金森病睡眠量表（PDSS）、帕金森病生活质量量表（PDQ-39）评估抑郁程度、睡眠和生活质量，酶联免 疫吸附法检测两组患者血清炎症因子水平。结果　 治疗 12 周后，观察组HAMD评分、PDQ-39 评分、炎症因子（IL-6、 IL-1β、IL-8）水平均明显低于对照组，而PDSS评分高于对照组（P<0.01 或 0.05）。结论 rTMS联合普拉克索治疗中晚期 PD合并抑郁可减轻抑郁程度，提高睡眠和生活质量。

Abstract:

Abstract: Objective To observe the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) and pramipexole in mid and late Parkinson’s disease (PD) with depression. Methods 92 patients with mid and late PD and depression were randomly treated with pramipexole (control group) or rTMS plus pramipexole (observation group) for 12 weeks. Depression, sleep quality, quality of life, and serum inflammatory factors were detected by Hamilton Depression Scale (HAMD), Parkinson’s Disease Sleep Scale (PDSS), Parkinson’s Disease Quality of Life Scale (PDQ-39), and enzymelinked immunosorbent assay, respectively. Results After 12 weeks of treatment, HAMD, PDQ-39 and inflammatory factors (IL-6, IL-1β and IL-8) were lower but PDSS was higher in observation group compared with control group (P<0.01 or 0.05). Conclusion Combined rTMS and pramipexole can improve depression, sleep quality and quality of life in patients with mid and late PD and depression.